BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22103888)

  • 1. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
    Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
    Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
    Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
    Kunisaki C; Takahashi M; Ono HA; Oshima T; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
    Oncology; 2012; 83(4):183-91. PubMed ID: 22890015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status.
    Hwang JE; Kim HN; Kim DE; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    Exp Ther Med; 2012 Oct; 4(4):562-568. PubMed ID: 23170106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.
    Shim HJ; Yun JY; Hwang JE; Bae WK; Cho SH; Chung IJ
    Gastric Cancer; 2011 Aug; 14(3):249-56. PubMed ID: 21431297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
    Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
    Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding.
    Yuan SQ; Nie RC; Chen YM; Qiu HB; Li XP; Chen XJ; Xu LP; Yang LF; Sun XW; Li YF; Zhou ZW; Chen S; Chen YB
    Oncol Lett; 2018 Apr; 15(4):4193-4200. PubMed ID: 29541185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
    Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
    Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
    BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
    Hwang EC; Hwang IS; Yu HS; Kim SO; Jung SI; Hwang JE; Kang TW; Kwon DD; Park K; Ryu SB
    Jpn J Clin Oncol; 2012 Oct; 42(10):955-60. PubMed ID: 22844127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
    Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
    Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
    Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Acta Haematol; 2015; 133(1):10-7. PubMed ID: 24969101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study.
    Miura T; Matsumoto Y; Hama T; Amano K; Tei Y; Kikuchi A; Suga A; Hisanaga T; Ishihara T; Abe M; Kaneishi K; Kawagoe S; Kuriyama T; Maeda T; Mori I; Nakajima N; Nishi T; Sakurai H; Morita T; Kinoshita H
    Support Care Cancer; 2015 Nov; 23(11):3149-56. PubMed ID: 25777319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
    Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
    Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
    Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
    Sano A; Sohda M; Hosoi N; Tateno K; Watanabe T; Uchida S; Nakazawa N; Osone K; Okada T; Shiraishi T; Sakai M; Ogawa H; Shirabe K; Saeki H
    Anticancer Res; 2023 Nov; 43(11):5205-5213. PubMed ID: 37909978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.